Intarcia names new vice president of clinical research

In his new role, Dr Luskey will lead the clinical development of Intarcia’s proprietary drug development programs including Omega Duros therapy for hepatitis C and ITCA 650 for the treatment of type 2 diabetes.

Dr Luskey has spent more than 13 years in academic medicine prior to holding leadership positions with several biopharmaceutical companies where he directed the development of new therapies for the treatment of diabetes.

Dr Luskey has received his medical education at the University of Texas Southwestern Medical School in Dallas. Dr Luskey trained in internal medicine with a subspecialty in endocrinology and metabolism.

Ms Leung said: “Ken’s drug development experience and expertise in the areas of diabetes and metabolic diseases are tremendous assets as we prepare to initiate clinical development of ITCA 650 for the treatment of type 2 diabetes. We look to his significant clinical and development expertise as we bring Omega DUROS therapy into later stages of development as well as expand the company’s pipeline in the metabolic diseases area.”

Intarcia is currently conducting a Phase I study of Omega Duros therapy in combination with ribavirin for the treatment of patients with hepatitis C virus genotype-1 who have failed prior standard of care treatment.